MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Biological diversity of ovarian cancer

Back to overy Blogs list Cancer blog  


Subscribe To Overy RSS Feed  RSS content feed What is RSS feed?

Biological diversity of ovarian cancer




Cancer prevention experts have long been frustrated by the lack of a meaningful way to screen women for ovary cancer. It is a relatively rare disease that often progresses with few symptoms until it is too late for potentially curative therapys, and elevated values of the most usually used biomarker used in screening, CA125, are also correlation to other disorders.

Now, researchers at the Duke Cancer Institute say that incorporating the latest information about the biological diversity of ovary cancer appears to lessen the potential value of screening even further.



Biological diversity of ovarian cancer

"I feel that what this and other studies are telling us is that we will have to do a whole lot more than screening to protect women from this terrible disease," said Laura Havrilesky, MD, an associate professor of gynecologic oncology at Duke and the main author of the study appearing in the journal CANCER "We need to work harder to find better approaches to screening and also consider the potential value of preventive strategies." .

Until recently, ovary cancer has been regarded as a single disease. But studies at Duke and elsewhere have shown that it has at least two distinct subtypes, a slow-growing, indolent form, which takes months to years to move into an advanced stage, and a more aggressive variety driven by key gene mutations that gallops through stages I and II in about half that time.

Havrilesky led a research team that used information in the SEER database to create a decision model for screening for ovary cancer. The SEER database, maintained by the National Institutes of Health, includes information on cancer incidence, prevalence and survival in over a quarter of the U.S. population and breaks out ovary cancer by type.

They then validated the model using early data from a real-life study, the U.K. Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), a large, randomized trial that is using CA125 values and ultrasound to screen a general population of post-menopausal women for ovary cancer.

In conceptualizing ovary cancer as a single disease, the model predicted that screening women over the age of 50 in the United States could potentially lower cancer deaths by about 15 percent. But incorporating the two subtype concept, the model predicted deaths would fall by only 11 percent.

Havrilesky says it just makes sense: Screening is more likely to pick up a greater number of slow-growing, as opposed to fast-growing tumors, because indolent cancers remain in a more treatable early stage almost twice as long as their more virulent counterparts. "But catching and successfully treating the slower-growing cancers isn't going to do as much to reduce deaths from ovary cancer as much as catching the more lethal tumors would do."

In an accompanying editorial, Patricia Hartge, MA, ScD, a senior investigator in the Division of Cancer Epidemiology and Genetics at the National Cancer Institute, notes the modest benefit of screening for a general population, but says that screening for women at higher risk of ovary cancer those who carry mutations known to be correlation to the disease or who have a family history of it presents a more hopeful picture.

But Havrilesky is not so sure. She says screening in even the highest risk population has still not been proven successful and says other options are under study that may hold merit.

'We know that women who take oral contraceptives have a reduced risk of ovary cancer, and the Duke Evidence-Based Practice Center is currently doing a systematic review and model to determine if this might be a reasonable approach for some women."


Posted by: Emily    Source




Did you know?
Cancer prevention experts have long been frustrated by the lack of a meaningful way to screen women for ovary cancer. It is a relatively rare disease that often progresses with few symptoms until it is too late for potentially curative therapys, and elevated values of the most usually used biomarker used in screening, CA125, are also correlation to other disorders.

Medicineworld.org: Biological diversity of ovarian cancer

Ectopic pregnancy| Hyperemesis gravidarum vomiting of pregnancy| Obgyn| Menopause symptoms| Pre eclampsia| Seizures in pregnancy| Spontaneous abortion miscarriage| Symptoms of pregnancy| Ovariancancer| Ovarian cancer statistics| Risk factors for ovarian cancer| Role of radiation therapy in the treatment of ovarian cancer| Role of screening in ovarian cancer| Staging of ovarian cancer| Symptoms of ovarian cancer| Treatment of advanced stage ovarian cancer| Treatment of early stage ovarian cancer| Treatment of ovarian cancer| Treatment of recurrent ovarian cancer| What causes ovarian cancer| Who is more prone to ovarian cancer|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.